Potential US pharma import tariffs could raise prices, stifle innovation, and revolutionise how the industry produces drugs.

AstraZeneca AZN stock has declined 6.4% in the past three months. Although AstraZeneca faces its share of challenges, a ...

Pfizer, on the other hand, with its improving growth prospects, rising estimates, cheaper valuation, and higher dividend ...